Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Histidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.30 |
| ▸ | CTSC | P53634 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Histidine SCHEMBL27660744 | 1.00 | CYP3A4 (0.30) | CYP3A4SLC7A5CTSCCYP1A2 | |
| Histidine SCHEMBL19809592 | 0.96 | — | — | |
| Histidine SCHEMBL28801818 | 0.94 | — | — | |
| Histidine SCHEMBL27660746 | 0.94 | SLC7A5 (0.31) | CYP3A4SLC7A5CTSCCYP1A2 | |
| Histidine SCHEMBL16444321 | 0.93 | CYP3A4 (0.32) | CYP3A4SLC7A5CTSCCYP1A2 | |
| Histidine SCHEMBL2586200 | 0.93 | SLC7A5 (0.35) | CYP3A4SLC7A5CTSCCYP1A2 | |
| Histidine SCHEMBL27902238 | 0.93 | SLC7A5 (0.35) | CYP3A4SLC7A5CTSCCYP1A2 | |
| D-Histidine SCHEMBL11606906 | 0.93 | SLC7A5 (0.35) | CYP3A4SLC7A5CTSCCYP1A2 | |
| Histidine SCHEMBL2586203 | 0.93 | SLC7A5 (0.35) | CYP3A4SLC7A5CTSCCYP1A2 | |
| Histidine SCHEMBL17685559 | 0.90 | GSR (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150141626-A1 | REDUCING THE IMMUNOGENICITY OF FUSION PROTEINS | MERCK PATENT GMBH (DE) | 2015-05-21 | — | — | US | disclosed |
| US-8926973-B2 | Reducing the immunogenicity of fusion proteins | MERCK PATENT GMBH (DE) | 2015-01-06 | — | — | US | disclosed |
| US-20120309936-A1 | REDUCING THE IMMUNOGENICITY OF FUSION PROTEINS | MERCK PATENT GMBH (DE) | 2012-12-06 | — | — | US | disclosed |
| US-7973150-B2 | Reducing the immunogenicity of fusion proteins | MERCK PATENT GMBH (DE) | 2011-07-05 | — | — | US | disclosed |
| EP-2311882-A1 | Reducing the immunogenicity of fusion proteins | Merck Patent GmbH (DE) | 2011-04-20 | — | — | EP | disclosed |
| EP-1373301-B1 | REDUCING THE IMMUNOGENICITY OF FUSION PROTEINS | MERCK PATENT GMBH (DE) | 2010-12-01 | — | — | EP | disclosed |
| US-20100016562-A1 | REDUCING THE IMMUNOGENICITY OF FUSION PROTEINS | MERCK PATENT GMBH | 2010-01-21 | — | — | US | disclosed |
| US-7601814-B2 | Reducing the immunogenicity of fusion proteins | MERCK PATENT GMBH (DE) | 2009-10-13 | — | — | US | disclosed |
| US-20060025573-A1 | Reduce binding to epitope to fusion protein; reduce its ability to interact with a T cell receptor; use in immunotherapy | MERCK PATENT GMBH (DE) | 2006-02-02 | — | — | US | disclosed |
| US-6992174-B2 | Reducing the immunogenicity of fusion proteins | EMD LEXIGEN RESEARCH CENTER CORP. (US) | 2006-01-31 | — | — | US | disclosed |
| US-20030166877-A1 | Reduce binding to epitope to fusion protein | LEXIGEN PHARMACEUTICALS CORP. (US) | 2003-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016562-A1 | REDUCING THE IMMUNOGENICITY OF FUSION PROTEINS | CD74, MICA, HLA-DRB1 | CYP3A4 4843/4885SLC7A5 1778/4885CTSC 1614/4885 |
| US-20150141626-A1 | REDUCING THE IMMUNOGENICITY OF FUSION PROTEINS | CD74, MICA, HLA-DRB1 | CYP3A4 4843/4885SLC7A5 1778/4885CTSC 1614/4885 |
| US-20030166877-A1 | Reduce binding to epitope to fusion protein | CD74, MICA, HLA-DRB1 | CYP3A4 4864/4885SLC7A5 1626/4885CTSC 1893/4885 |
| US-20120309936-A1 | REDUCING THE IMMUNOGENICITY OF FUSION PROTEINS | CD74, MICA, HLA-DRB1 | CYP3A4 4843/4885SLC7A5 1778/4885CTSC 1614/4885 |
| US-20060025573-A1 | Reduce binding to epitope to fusion protein; reduce its ability to interact with a T cell receptor; use in immunotherapy | CD74, MICA, TAP2 | CYP3A4 4843/4885SLC7A5 2115/4885CTSC 2456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.